“The risk/reward for BioNTech (NASDAQ:BNTX) has become less attractive,” says HC Wainwright’s Raghuram Selvaraju, downgrading to Neutral from Buy.
He notes many open questions remain on the company’s mRNA-based Covid-19 vaccine. Among them: The strength and duration of neutralizing antibodies and T cell responses that may be generated in human trials, and whether long-term protection is effective.
At last night’s close, the company is worth $15B – less than Moderna’s $24B, but still a bit perky for Selvaraju.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.